Dalan Animal Health is a bioscience company that created the world’s first USDA-approved vaccine for honeybees and is now advancing what it says will be the first commercial shrimp vaccine. Built on its proprietary Innate Immunity Platform, the firm targets conserved pattern-recognition receptors shared across animal species to deliver broad-spectrum disease protection. After launching its honeybee vaccine, the company is focusing on regulatory approval, manufacturing scale-up, and commercial rollout of its shrimp vaccine to help mitigate the estimated $4 billion in annual shrimp industry losses from disease. Concurrently, Dalan is investigating platform extensions into poultry and additional aquaculture species to reduce antibiotic dependence in food production. The business operates globally, including a European subsidiary, Dalan Bio SL, which recently secured a €250 K grant to conduct pan-European surveillance of honeybee diseases. Recognition for its technology includes TIME’s Best Inventions, Fast Company’s Next Big Things in Tech, and SVG THRIVE Global Impact Challenge winner (2025). The latest financing leaves the company capitalized to complete shrimp vaccine commercialization and expand its product pipeline, though no revenue or user metrics were disclosed.

Total raised

$13M

Funding rounds

5

Latest round

Grant

Latest activity

Nov 2025